Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma

Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era

“…Those requiring ≥ two salvage lines prior to HCT also received post HCT Bv consolidation; however, with no statistical significance 13 (59%) vs. 10 (30%) ( p = 0.1). The median (range) of total salvage cycles prior to HCT of patients who received single salvage was 2 (2–3) and for those who received ≥ 2 salvage lines was 4 [2] , [3] , [4] , [5] , [6] , [7] , [8] . ESHAP was the most commonly used first salvage in both cohorts, albeit with a trend towards higher use in the ≥ 2 salvage lines cohort at 49 vs. 88%, respectively ( p = 0.07).…”

“…A number of factors have been found to exhibit a negative prognostic including poor performance status, refractory status post first line therapy, extra-nodal disease and the need for multiple chemotherapy regimens prior to HCT [3] . More recently, the presence of metabolically active disease prior to HCT has emerged as a robust prognostic indicator of worse outcome [4] , [5] , [6] .…”

Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume

“…The prognostic value of pre‐transplant DS has been previously reported in relapsed/refractory cHL 11,15,16 . However, no specific studies have addressed the prognostic impact of the residual metabolic tumor burden prior to salvage ASCT and its added value to DS and other risk factors to stratify patients for the risk of post‐transplant treatment failure.…”

Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma

“…Salvage therapy followed by autologous hematopoietic stem cell transplantation (HCT) can be curative in relapsed/refractory classical Hodgkin lymphoma (cHL) [1]. Complete response (CR) prior to HCT, particularly complete metabolic response (CMR) indicated by a negative positron emission tomography/computed tomography (PET/CT) scan, is highly prognostic of post-transplant outcome [2, 3]. Thus optimization of disease status prior to HCT is highly desirable.…”

“…Autologous HCT is a potentially curative therapy in R/R cHL with approximately half of patients achieving prolonged remissions following standard salvage therapy followed by HCT [10]. Importantly, CMR status pre-HCT indicated by a negative PET/CT has been shown to strongly correlate with a superior outcome by a number of groups [2, 3]. Thus, optimization of disease status prior to HCT leads to higher remission rates.…”